Shares

8 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2021

Nov 12, 2021

SELL
$90.24 - $124.05 $251,859 - $346,223
-2,791 Closed
0 $0
Q2 2021

Aug 05, 2021

BUY
$93.66 - $139.27 $261,405 - $388,702
2,791 New
2,791 $347,000
Q2 2019

Aug 06, 2019

SELL
$89.51 - $118.04 $1.51 Million - $1.98 Million
-16,815 Closed
0 $0
Q1 2019

May 15, 2019

BUY
$61.98 - $96.5 $747,726 - $1.16 Million
12,064 Added 253.93%
16,815 $1.46 Million
Q4 2018

Feb 12, 2019

BUY
$56.04 - $82.66 $266,246 - $392,717
4,751 New
4,751 $300,000
Q3 2018

Nov 13, 2018

SELL
$48.29 - $80.6 $515,882 - $861,049
-10,683 Closed
0 $0
Q2 2018

Aug 09, 2018

BUY
$37.84 - $69.96 $93,729 - $173,290
2,477 Added 30.19%
10,683 $639,000
Q1 2018

May 11, 2018

BUY
$39.82 - $57.53 $326,762 - $472,091
8,206 New
8,206 $331,000

Others Institutions Holding EXAS

About EXACT SCIENCES CORP


  • Ticker EXAS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Diagnostics & Research
  • Shares Outstandng 176,960,000
  • Market Cap $10.2B
  • Description
  • Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX, a gene expression tests for...
More about EXAS
Track This Portfolio

Track Gsa Capital Partners LLP Portfolio

Follow Gsa Capital Partners LLP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Gsa Capital Partners LLP, based on Form 13F filings with the SEC.

News

Stay updated on Gsa Capital Partners LLP with notifications on news.